Details of the Drug

General Information of Drug (ID: DM4O2Z7)

• Drug Name: Cyclophosphamide
• Synonyms: ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Central nervous system neoplasm	N.A.	Approved	[1]
Glioblastoma	2A00	Approved	[1]
Immunodeficiency	4A00-4A85	Approved	[1]
Inflammatory breast cancer	2C62	Approved	[1]
Lupus nephritis	4A40.0Y	Approved	[1]
Lymphoma	2A80-2A86	Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]
Retinoblastoma	2D02.2	Investigative	[1]
Scleroderma	4A42	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01AA01: Cyclophosphamide
  L01AA: Nitrogen mustard analogues
  L01A: ALKYLATING AGENTS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 261.079
  Logarithm of the Partition Coefficient (xlogp); 0.6
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: 74% of drug becomes completely available to its intended biological destination(s) [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.1 mL/min/kg [5]
  Elimination: 6.5% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 12 hours [5]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.15051 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.87% [5]
  Vd: The volume of distribution (Vd) of drug is 30-50 L []
  Water Solubility: The ability of drug to dissolve in water is measured as 40 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cardiotoxicity	Not Available	TNNI2	OTGGZFSC	[7]
Haemolytic anaemia	Not Available	G6PD	OT300SMK	[7]
Porphyrin metabolism disorder	Not Available	UROD	OTPP4UH5	[7]
Pulmonary toxicity	Not Available	SOD1	OT39TA1L	[7]
Pulmonary toxicity	Not Available	GPX1	OTE2O72Q	[7]
Pulmonary toxicity	Not Available	GSR	OTM2TUYM	[7]

• Chemical Identifiers:
  Formula: C7H15Cl2N2O2P
  IUPAC Name: N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
  Canonical SMILES: C1CNP(=O)(OC1)N(CCCl)CCCl
  InChI: InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
  InChIKey: CMSMOCZEIVJLDB-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2907
  ChEBI ID: CHEBI:4027
  CAS Number: 50-18-0
  UNII: 6UXW23996M
  DrugBank ID: DB00531
  TTD ID: D0CT9C
  VARIDT ID: DR00425
  INTEDE ID: DR0391
  ACDINA ID: D00157
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[13]
Cytochrome P450 2B6 (CYP2B6) Main DME	DEPKLMQ	CP2B6_HUMAN	Substrate	[14]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[15]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[16]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[17]
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Gene/Protein Processing	[18]
Alanine aminotransferase 2 (GPT2)	OTS5VF7N	ALAT2_HUMAN	Gene/Protein Processing	[19]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Gene/Protein Processing	[20]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Drug Response	[21]
Aldehyde dehydrogenase, mitochondrial (ALDH2)	OTKJ9I3N	ALDH2_HUMAN	Gene/Protein Processing	[20]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Gene/Protein Processing	[20]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[19]
Angiopoietin-1 (ANGPT1)	OTVZ1NG3	ANGP1_HUMAN	Gene/Protein Processing	[20]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[22]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC2	5.9963	11.05	1.3936	6.184
A-673	GDSC2	4.2034	6.0899	2.5853	2.6382
ES8	GDSC2	4.5289	6.6633	2.5177	2.4718
NY	GDSC2	4.5825	7.658	2.0928	4.7852
EW-7	GDSC2	4.5868	6.6226	2.5684	2.1142
EW-24	GDSC2	4.819	6.9697	2.5428	1.9262
ES1	GDSC2	5.0375	7.0333	2.6261	1.284
HOS	GDSC2	5.0506	6.5411	2.8257	0.5127
SK-ES-1	GDSC2	5.0509	6.484	2.8472	0.4465
ES7	GDSC2	5.0637	7.7602	2.3312	2.6669
EW-1	GDSC2	5.1617	10.0203	1.3539	7.9106
MG-63	GDSC2	5.2408	7.9348	2.3501	2.3355
CAL-72	GDSC2	5.2592	10.6632	1.1131	9.0596
ES6	GDSC2	5.2766	12.401	0.2902	13.3891
HuO-3N1	GDSC2	5.3337	8.3318	2.2283	2.8205
ES4	GDSC2	5.4114	7.7581	2.5087	1.4169
CADO-ES1	GDSC2	5.5	7.1119	2.7948	0.3687
U-CH2	GDSC2	5.5224	7.4235	2.6888	0.6571
EW-11	GDSC2	5.6877	9.5718	1.8788	4.1153
EW-18	GDSC2	5.6958	7.7675	2.6311	0.7339
EW-22	GDSC2	5.7091	7.8035	2.623	0.7515
CHSA8926	GDSC2	5.7538	7.4557	2.7684	0.3295
TC-71	GDSC2	5.7782	7.1259	2.8912	0.1112
G-292 clone A141B1	GDSC2	5.7833	8.0043	2.5779	0.8518
H-EMC-SS	GDSC2	5.8052	8.1886	2.5164	1.0506
EW-12	GDSC2	5.8189	7.6852	2.711	0.4392
CHSA0011	GDSC2	5.8624	8.5041	2.418	1.3763
HuO9	GDSC2	5.9203	8.5176	2.4387	1.2484
EW-13	GDSC2	5.9899	7.9388	2.6855	0.4292
EW-3	GDSC2	6.0225	7.9848	2.6815	0.4254
SK-PN-DW	GDSC2	6.0808	8.234	2.6138	0.5719
SaOS-2	GDSC2	6.1772	7.8198	2.7956	0.1628
ES5	GDSC2	6.2398	8.2983	2.652	0.4084
CHSA0108	GDSC2	6.2667	8.7071	2.5136	0.7597
EW-16	GDSC2	6.2924	8.4328	2.6239	0.4526
NOS-1 [Human HNSCC]	GDSC2	6.4428	8.8395	2.5351	0.6089
CAL-78	GDSC2; CTRP2	8.6311	10.5408	6.3542	0.848
MHH-ES-1	GDSC2; CTRP2	9.0117	11.3245	6.2161	0.9905
SW1353	CTRP2	9.0432	14.4453	4.8297	5.9744
U2OS	GDSC2; CTRP2	9.2437	10.8956	6.4819	0.2553
SJSA-1	GDSC2; CTRP2	9.6621	22.9136	0.4014	16.6091

Cancer Drug Sensitivity Data Curated from 190 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	8.6804	13.4216	5.0767	5.4918
JM1	GDSC2	5.828	7.5861	2.7501	0.3428
SU-DHL-5	GDSC2	3.5204	5.0813	2.6017	4.0148
Karpas-1106P	GDSC2	3.5554	5.82	2.2618	6.0631
HL-60	GDSC2	3.6849	9.1503	0.7044	15.1574
SU-DHL-16	GDSC2	4.1168	8.0752	1.5708	8.9335
BONNA-12	GDSC2	4.1537	9.7982	0.7482	13.6489
697	GDSC2	4.2879	6.1562	2.606	2.376
WSU-NHL	GDSC2	4.3103	12.3485	-0.3964	19.0271
EoL-1	GDSC2	4.3945	9.0642	1.2882	9.9553
SUP-M2	GDSC2	4.4107	6.6027	2.4756	2.8984
SUP-B8	GDSC2	4.4308	12.0165	-0.1393	17.5211
P32/ISH	GDSC2	4.4321	6.125	2.7017	1.6427
JeKo-1	GDSC2	4.5557	8.0687	1.8813	6.0818
KOPN-8	GDSC2	4.561	7.7464	2.0374	5.1505
SIG-M5	GDSC2	4.5773	5.8602	2.8842	0.6456
YT	GDSC2	4.6561	6.4432	2.6829	1.4466
VAL	GDSC2	4.699	6.9774	2.4741	2.446
CA46	GDSC2	4.7414	8.4886	1.8041	6.1602
BALL-1	GDSC2	4.7905	6.7109	2.6382	1.4987
LP-1	GDSC2	4.8085	7.905	2.1189	4.2217
Hs 445	GDSC2	4.8221	6.6911	2.6624	1.3505
ME1	GDSC2	4.8283	6.8481	2.5996	1.6372
GA-10	GDSC2	4.8586	6.3281	2.8256	0.6427
RC-K8	GDSC2	4.864	6.9597	2.5705	1.7335
SCC-3	GDSC2	4.8641	6.2642	2.8525	0.5448
IM-9	GDSC2	4.8705	6.5759	2.7329	0.9931
TUR	GDSC2	4.9044	6.3291	2.8449	0.5434
NOMO-1	GDSC2	4.912	6.6629	2.7172	1.0194
BL-41	GDSC2	4.923	6.1443	2.9213	0.3046
Daudi	GDSC2	4.9268	6.6965	2.7105	1.0331
CTV-1	GDSC2	4.9458	7.328	2.4555	2.1954
MOLP-8	GDSC2	4.9533	6.746	2.7029	1.0399
GR-ST	GDSC2	4.9607	7.3924	2.4356	2.2759
EJM	GDSC2	4.9685	7.023	2.5967	1.4881
Loucy	GDSC2	4.9871	6.6182	2.769	0.7515
OCI-M1	GDSC2	5.0089	6.433	2.8491	0.4648
A3/Kawakami	GDSC2	5.0119	6.0568	2.9855	0.1346
JSC-1	GDSC2	5.0723	7.1844	2.5808	1.4472
SUP-B15	GDSC2	5.0887	6.9091	2.7	0.9313
MOLT-4	GDSC2	5.1008	6.777	2.757	0.7095
MY-M12	GDSC2	5.1451	8.1857	2.1888	3.2926
KY821	GDSC2	5.148	7.0378	2.6758	0.9756
TK [Human B-cell lymphoma]	GDSC2	5.1643	6.5863	2.8548	0.3663
Karpas-422	GDSC2	5.1709	6.6091	2.8491	0.3786
P30/OHK	GDSC2	5.173	7.4379	2.5252	1.5886
WIL2 NS	GDSC2	5.1995	6.6488	2.8458	0.3735
Karpas-231	GDSC2	5.2019	6.6719	2.8384	0.3925
OCI-Ly7	GDSC2	5.2169	6.533	2.8942	0.2489
OPM-2	GDSC2	5.2179	6.5677	2.8823	0.2753
JJN-3	GDSC2	5.225	6.5539	2.8898	0.2556
QIMR-WIL	GDSC2	5.261	9.0372	1.8729	4.8181
MLMA	GDSC2	5.2711	8.3791	2.1736	3.188
ST486	GDSC2	5.2748	6.7443	2.8405	0.3526
OCI-AML-3	GDSC2	5.3069	6.9418	2.7808	0.501
NK-92MI	GDSC2	5.3328	7.2356	2.6802	0.8131
Jiyoye	GDSC2	5.3408	7.8699	2.4286	1.8436
DND-41	GDSC2	5.3504	7.6167	2.5372	1.3556
EB2	GDSC2	5.4234	7.0669	2.7813	0.439
BC-3	GDSC2	5.4543	6.9557	2.8334	0.2961
HAL-01	GDSC2	5.4596	7.627	2.5833	1.0731
Farage	GDSC2	5.4743	16.3779	-1.5107	20.7256
H9	GDSC2	5.4974	7.2865	2.7299	0.5462
HC-1	GDSC2	5.4978	7.7852	2.5379	1.218
RL	GDSC2	5.5132	6.8953	2.8763	0.1909
LC4-1	GDSC2	5.5197	7.7744	2.5521	1.1435
Namalwa	GDSC2	5.5271	6.9911	2.848	0.2399
KMOE-2	GDSC2	5.5444	7.2446	2.764	0.4274
MN-60	GDSC2	5.5638	7.8594	2.5383	1.1598
A4/Fukuda	GDSC2	5.6179	7.1728	2.8177	0.2717
NU-DUL-1	GDSC2; CTRP2	5.618	8.1909	3.9198	4.3132
L-428	GDSC2	5.6464	7.2521	2.8004	0.2985
RPMI-6666	GDSC2	5.6671	7.1473	2.8447	0.2049
MHH-CALL-2	GDSC2	5.673	7.1402	2.8493	0.1953
BE-13	GDSC2	5.7035	7.5157	2.7276	0.4487
Granta-519	GDSC2	5.7051	7.4033	2.7687	0.3473
KG-1	GDSC2	5.7232	7.3517	2.7938	0.2858
U266B1	GDSC2	5.7259	7.3915	2.7808	0.3125
CRO-AP2	GDSC2	5.7339	7.415	2.7754	0.3213
Kasumi-1	GDSC2	5.7394	7.6379	2.6971	0.513
ML-2	GDSC2	5.746	7.5878	2.718	0.4542
Ramos.2G6.4C10	GDSC2	5.7546	7.1026	2.8909	0.1157
CESS	GDSC2	5.7825	7.9887	2.5836	0.8335
BC-1	GDSC2	5.7839	7.867	2.6301	0.6837
OCI-Ly19	GDSC2	5.8165	7.7045	2.7031	0.4604
ROS-50	GDSC2	5.8262	8.1502	2.5404	0.9506
ATN-1	GDSC2	5.839	7.5009	2.7842	0.2675
MHH-PREB-1	GDSC2	5.8736	7.3245	2.8573	0.1376
ARH-77	GDSC2	5.884	7.289	2.8729	0.1157
NKM-1	GDSC2	5.8923	7.9093	2.6581	0.5438
ALL-PO	GDSC2	5.9065	8.2537	2.535	0.9136
ALL-SIL	GDSC2	6.0103	7.5687	2.8224	0.1589
DG-75	GDSC2	6.0193	7.8722	2.7204	0.3385
CCRF-CEM	GDSC2	6.0373	7.6403	2.8075	0.175
K-562	GDSC2	6.1004	7.7552	2.7906	0.1865
U-698-M	GDSC2	6.1328	7.7621	2.7996	0.1662
PL-21	GDSC2	6.1677	8.6366	2.4993	0.862
DB	GDSC2	6.1878	7.9101	2.7686	0.2006
VL51	GDSC2	6.2226	7.9199	2.7775	0.1793
SUP-HD1	GDSC2	6.2941	8.1625	2.7197	0.2551
HH [Human lymphoma]	GDSC2	6.3428	8.6678	2.5585	0.5942
Karpas-45	GDSC2	6.3485	7.9338	2.8164	0.1083
CTB-1	GDSC2	6.4985	9.0519	2.4792	0.7342
MEG-01	GDSC2	6.8235	8.6321	2.7456	0.1165
SK-MM-2	GDSC2; CTRP2	7.7057	9.4264	5.456	0.6345
MC116	GDSC2; CTRP2	7.7425	12.1131	5.0494	7.0244
NCO2	CTRP2	7.7492	9.8825	6.1433	2.515
KMS-28BM	CTRP2	7.7931	12.2385	5.0255	7.0398
MHH-CALL-3	CTRP2	7.9079	12.2185	5.1203	6.4606
SU-DHL-10	GDSC2; CTRP2	8.0439	9.8123	6.3587	1.333
SU-DHL-1	GDSC2; CTRP2	8.1343	9.0224	6.7295	0.1673
RS4;11	GDSC2; CTRP2	8.1781	10.791	5.1251	1.3088
KMS-34	CTRP2	8.1951	9.7974	6.4473	0.8903
Mono-Mac-6	GDSC2; CTRP2	8.2278	11.0698	5.8934	2.8719
SUP-T11	CTRP2	8.31	10.61	6.154	1.7948
BV-173	GDSC2; CTRP2	8.3375	10.7814	6.0928	1.9891
OCI-AML-2	GDSC2; CTRP2	8.3449	9.9165	6.4724	0.6994
P3HR-1	CTRP2	8.3625	10.2775	6.3293	1.1346
DEL	GDSC2; CTRP2	8.4028	9.5493	6.6425	0.2392
SR	GDSC2; CTRP2	8.4157	10.2936	6.3501	1.0224
MOLT-16	GDSC2; CTRP2	8.4345	10.7222	6.1746	1.5959
KMS-26	CTRP2	8.4452	9.8211	6.5569	0.4109
Karpas-299	GDSC2; CTRP2	8.4646	9.9286	6.5233	0.4843
SU-DHL-4	GDSC2; CTRP2	8.4827	9.8788	6.5508	0.4066
MOLM-16	GDSC2; CTRP2	8.5159	11.0418	6.0786	1.8542
MOLM-6	CTRP2	8.5387	11.377	5.9413	2.3272
SU-DHL-6	GDSC2; CTRP2	8.5422	10.8038	6.1976	1.4161
KMS-27	CTRP2	8.5427	10.0544	6.5087	0.4792
NCI-H929	GDSC2; CTRP2	8.5543	13.562	4.9244	6.2764
KMS-18	CTRP2	8.5582	10.8026	6.2067	1.3715
P12-Ichikawa	GDSC2; CTRP2	8.6681	9.9053	6.6171	0.1973
L-363	GDSC2; CTRP2	8.6855	13.2012	5.1848	5.0572
HPB-ALL	CTRP2	8.6925	10.7126	6.3133	0.9262
P31/FUJ	GDSC2; CTRP2	8.7802	10.0094	6.6227	0.1581
EM-2	GDSC2; CTRP2	8.7979	10.1876	6.5652	0.2479
MM1.S	GDSC2; CTRP2	8.8012	10.2637	6.5384	0.2974
KE-37	GDSC2; CTRP2	8.8282	10.1269	6.5989	0.182
Reh	GDSC2; CTRP2	8.8404	10.0423	6.6335	0.1295
PF-382	GDSC2; CTRP2	8.8411	11.2841	6.1483	1.3235
AMO1	GDSC2; CTRP2	8.8581	10.1705	6.5947	0.1807
SKM-1	GDSC2; CTRP2	8.8666	10.1497	6.6053	0.1626
RPMI-8402	GDSC2; CTRP2	8.8806	10.4337	6.5074	0.3294
WSU-DLCL2	GDSC2; CTRP2	8.8894	9.9984	6.6663	0.0825
L-540	GDSC2; CTRP2	8.9139	13.621	5.1348	4.9532
HT	GDSC2; CTRP2	8.9276	9.9708	6.689	0.0569
NALM-6	GDSC2; CTRP2	8.9464	10.7811	6.4029	0.5314
MOLM-13	GDSC2; CTRP2	8.9685	10.7184	6.4365	0.4436
JURL-MK1	CTRP2	8.9836	10.6993	6.4501	0.4074
U-937	CTRP2	8.9906	10.138	6.6544	0.0797
PL21	CTRP2	8.9956	10.8029	6.4157	0.4782
RCH-ACV	GDSC2; CTRP2	9.0062	13.7154	5.1494	4.7794
HEL	GDSC2; CTRP2	9.0141	10.116	6.6701	0.0626
Raji	GDSC2; CTRP2	9.0148	10.3953	6.5738	0.1727
KHM-1B	CTRP2	9.0168	10.4149	6.5676	0.1813
GDM-1	GDSC2; CTRP2	9.0413	11.2056	6.2781	0.798
KYO-1	CTRP2	9.0575	10.5361	6.5398	0.2136
MOLP-2	CTRP2	9.0811	11.8905	6.0143	1.5582
MV4-11	GDSC2; CTRP2	9.0871	15.2228	4.489	7.247
KMS-12-BM	GDSC2; CTRP2	9.1059	11.0691	6.3607	0.5539
Ki-JK	CTRP2	9.1215	10.706	6.5031	0.2556
Ri-1	CTRP2	9.1299	12.4332	5.8058	2.2123
NB4	GDSC2; CTRP2	9.1303	10.2026	6.6808	0.0432
HDLM-2	GDSC2; CTRP2	9.1491	11.0133	6.4004	0.4447
MHH-CALL-4	GDSC2; CTRP2	9.1644	13.49	5.3513	3.8203
KCL-22	GDSC2; CTRP2	9.1674	10.7156	6.5174	0.2193
RPMI-8226	GDSC2; CTRP2	9.1727	10.4996	6.5953	0.1132
DoHH2	GDSC2; CTRP2	9.1896	10.4342	6.6236	0.0817
Jurkat	GDSC2; CTRP2	9.2182	10.6321	6.5658	0.1396
Peer	CTRP2	9.2237	10.4992	6.6135	0.0866
THP-1	GDSC2; CTRP2	9.2376	10.6093	6.5807	0.1184
KE-97	CTRP2	9.2474	10.4469	6.6393	0.0615
SUP-T1	GDSC2; CTRP2	9.2529	10.6617	6.5681	0.1302
L-1236	GDSC2; CTRP2	9.2601	11.6886	6.1856	0.9168
EHEB	CTRP2	9.2779	11.053	6.438	0.3215
MOLT-13	GDSC2; CTRP2	9.2789	10.8795	6.5011	0.2152
CML-T1	GDSC2; CTRP2	9.3724	10.6538	6.613	0.0687
SU-DHL-8	GDSC2; CTRP2	9.3872	17.8551	3.4278	10.8654
LAMA-84	GDSC2; CTRP2	9.3879	11.0796	6.4711	0.2331
KM-H2	GDSC2; CTRP2	9.4087	10.7708	6.5861	0.0874
ME1	CTRP2	9.4598	10.9763	6.534	0.1331
KMS-21-BM	CTRP2	9.5021	10.9455	6.5595	0.0997
JVM-3	GDSC2; CTRP2	9.5307	11.0618	6.5299	0.1257
Ku812	GDSC2; CTRP2	9.5632	11.1867	6.4984	0.1562
TALL-1 [Human adult T-ALL]	GDSC2; CTRP2	9.6016	12.1033	6.1755	0.752
KMM-1	CTRP2	9.6788	11.6659	6.3719	0.3124
REC-1	CTRP2	9.6876	11.7001	6.3629	0.325
KMS-11	GDSC2; CTRP2	9.7234	11.8985	6.3044	0.4189
Mono-Mac-1	CTRP2	9.91	12.9277	5.989	1.0585
JVM-2	GDSC2; CTRP2	9.9279	11.8348	6.4057	0.2006
Karpas-620	GDSC2; CTRP2	10.685	22.764	1.9552	14.0164

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE8	CTRP2	7.5129	13.5804	3.419	9.0598
OE19	GDSC2	4.4702	7.8298	1.9382	5.9205
OE33	GDSC2	5.1461	7.3561	2.5459	1.5247
KYSE-150	GDSC2	5.301	6.9063	2.7916	0.4728
TE-11	GDSC2	5.318	7.1522	2.7059	0.7337
KYSE-510	GDSC2	5.4259	7.1025	2.7692	0.4711
EC-GI-10	GDSC2	5.7565	7.5525	2.7348	0.407
KYSE-450	GDSC2	5.8192	7.3461	2.8308	0.1892
TE-8	GDSC2	5.8294	7.7944	2.6753	0.5279
TE-5	GDSC2	5.9248	7.6605	2.7599	0.2885
KYSE-520	GDSC2	5.9251	8.4152	2.4808	1.0895
OE21	GDSC2	5.957	8.232	2.5644	0.7848
T.T	GDSC2	6.0339	7.6901	2.7892	0.2043
KYSE-270	GDSC2	6.0604	8.6395	2.4528	1.0902
TE-4	GDSC2; CTRP2	7.6577	14.319	3.1624	9.8977
TE-6	GDSC2; CTRP2	7.7167	17.7371	1.5265	16.1431
KYSE-70	GDSC2; CTRP2	8.9946	10.6446	6.4752	0.3508
KYSE-410	GDSC2; CTRP2	9.0127	12.1335	5.873	2.0911
KYSE-180	GDSC2; CTRP2	9.0989	10.8958	6.4239	0.4155
TE-1	GDSC2; CTRP2	9.156	10.7394	6.5044	0.2433
TE-9	GDSC2; CTRP2	9.4284	10.6072	6.6475	0.0402
COLO 680N	GDSC2; CTRP2	9.4825	10.8754	6.5764	0.0866
TE-10	GDSC2; CTRP2	9.6133	11.6366	6.3569	0.3587
KYSE-140	GDSC2; CTRP2	9.669	11.7099	6.352	0.3496

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYAE-1	GDSC2	4.4637	6.7869	2.4232	3.1024
SK-GT-4	GDSC2	4.7203	7.7096	2.155	4.1723
KYSE-50	GDSC2	4.9834	7.0822	2.5794	1.5508
FLO-1	GDSC2	5.5631	8.6546	2.2105	2.6109
ESO-26	GDSC2	5.5673	7.4254	2.7065	0.5765
OACM5.1 C	GDSC2	5.8892	8.0978	2.5868	0.7554
HCE-4	GDSC2	5.8931	13.0029	0.42	11.4375
ESO-51	GDSC2	6.0088	7.9351	2.694	0.4012
KYSE-220	GDSC2	6.0602	8.1695	2.6292	0.5405
OACP4 C	GDSC2	6.7049	8.6236	2.7076	0.1802
TE-12	GDSC2	6.9136	9.2919	2.5522	0.3864

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC2	5.1525	7.6603	2.4214	2.0985

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-N-DZ	GDSC2	3.9578	6.8125	2.074	6.2299
SJNB-14	GDSC2	4.1752	6.0304	2.5955	2.6301
SK-N-FI	GDSC2	4.2476	6.7287	2.3144	4.1354
SJNB-5	GDSC2	4.4567	6.4606	2.567	2.3175
SK-N-AS	GDSC2	4.4689	6.8625	2.3916	3.2717
SJNB-10	GDSC2	4.4966	7.0511	2.3216	3.6216
TGW	GDSC2	4.5548	6.5653	2.5758	2.1218
NB69	GDSC2	4.7077	7.9147	2.0521	4.7849
CHP-134	GDSC2	4.8149	6.3609	2.7933	0.7989
SK-N-MC-IXC	GDSC2	4.9451	5.9269	3.0063	0.1171
KP-N-RT-BM-1	GDSC2	4.9523	7.7503	2.2736	3.1326
KP-N-YN	GDSC2	5.4421	7.4944	2.6275	0.9215
SK-N-SH	GDSC2	5.4505	7.3702	2.679	0.7352
GOTO	GDSC2	5.4651	7.5357	2.6215	0.926
IMR-5	GDSC2	5.5186	7.2551	2.7499	0.4777
NB(TU)1	GDSC2	5.5278	7.7459	2.567	1.0796
NH-12	GDSC2	5.6355	7.6435	2.6528	0.7018
CHP-212	GDSC2	5.6542	7.5886	2.6811	0.6036
SJNB-17	GDSC2	5.655	7.6324	2.6651	0.6518
SJNB-13	GDSC2	5.6831	7.7932	2.616	0.7912
SJNB-7	GDSC2	5.72	7.2478	2.829	0.2184
SJNB-6	GDSC2	5.8188	7.6182	2.7351	0.3808
SK-N-BE(2)-M17	GDSC2	5.9592	7.7202	2.7516	0.294
SJNB-12	GDSC2	5.9755	8.5236	2.4607	1.1242
LA-N-6	GDSC2	6.0184	7.9359	2.6974	0.3897
KP-N-YS	GDSC2	6.0297	8.1047	2.6409	0.524
SiMa	GDSC2	6.0433	7.6351	2.8114	0.1679
GI-ME-N	GDSC2	6.2796	8.9854	2.4138	1.0709
CHP-126	GDSC2; CTRP2	8.1147	10.4187	6.1251	2.1195
MHH-NB-11	GDSC2; CTRP2	8.48	10.8877	6.1268	1.7194
Kelly	GDSC2; CTRP2	8.7522	10.6227	6.3782	0.7013
NB1	GDSC2; CTRP2	8.9338	10.1039	6.6459	0.097
KP-N-SI9s	CTRP2	9.0505	10.6364	6.5007	0.2822

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-1079	CTRP2	7.6651	10.1834	5.9402	3.4611
HuH-28	CTRP2	8.3673	10.4525	6.256	1.3777
SNU-478	CTRP2	8.3744	10.5915	6.1988	1.5697
SNU-308	CTRP2	8.7657	10.159	6.5629	0.2629
SNU-1196	CTRP2	9.217	10.6401	6.5626	0.1438
HuCC-T1	GDSC2; CTRP2	9.2181	10.7431	6.5268	0.1922

Cancer Drug Sensitivity Data Curated from 53 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC1599	GDSC2	4.1537	6.3575	2.4288	3.6445
MDA-MB-468	GDSC2	4.2	6.4817	2.4002	3.722
BT-20	GDSC2	4.3841	6.7219	2.4045	3.349
ZR-75-30	GDSC2	4.3981	6.6223	2.4591	3.0133
Hs 578T	GDSC2	4.4837	8.2412	1.7502	7.0121
COLO 824	GDSC2	4.7041	8.1315	1.9484	5.3924
DU4475	GDSC2	4.7331	6.1659	2.8335	0.7114
HCC1419	GDSC2	4.7459	15.5893	-1.6692	22.9994
HCC1187	GDSC2	4.8776	7.0223	2.5509	1.8114
HCC70	GDSC2	4.9157	7.2043	2.4929	2.0485
UACC-812	GDSC2	4.9177	6.9504	2.6017	1.5222
EFM-19	GDSC2	4.9377	10.885	0.7876	11.5388
MDA-MB-157	GDSC2	5.0439	7.9839	2.2214	3.2718
HCC1428	GDSC2	5.0746	6.6062	2.8111	0.5443
MFM-223	GDSC2	5.0884	7.0363	2.649	1.137
Evsa-T	GDSC2	5.1282	6.7983	2.7606	0.6775
BT-474	GDSC2	5.1873	6.5995	2.859	0.3446
HCC1500	GDSC2	5.198	8.0555	2.2752	2.7671
BT-483	GDSC2	5.2322	6.9561	2.7444	0.6613
HCC2218	GDSC2	5.2616	9.3781	1.7171	5.6805
MDA-MB-330	GDSC2	5.2656	7.3493	2.6054	1.1528
HCC38	GDSC2	5.3054	7.093	2.7233	0.6835
HCC2157	GDSC2	5.3507	7.0649	2.7527	0.5606
OCUB-M	GDSC2	5.4271	7.3817	2.6645	0.8005
MDA-MB-436	GDSC2	5.4282	7.509	2.6157	0.9759
MDA-MB-453	GDSC2	5.4742	7.8398	2.5051	1.3724
UACC-893	GDSC2	5.5261	8.0921	2.4272	1.6525
EFM-192A	GDSC2	5.5294	7.2405	2.7596	0.4461
YMB-1-E	GDSC2	5.5481	11.8678	0.7315	10.5323
MDA-MB-361	GDSC2	5.6277	7.5993	2.6663	0.6642
MRK-nu-1	GDSC2	5.6527	7.1797	2.8281	0.2397
MDA-MB-175-VII	GDSC2	5.6647	7.4373	2.7409	0.432
MDA-MB-415	GDSC2	5.7191	7.8442	2.6118	0.7816
AU565	GDSC2	5.8524	8.5479	2.396	1.4727
BT-549	GDSC2	6.0134	8.3225	2.5537	0.7843
HCC1569	GDSC2	6.0338	8.3551	2.5499	0.7841
CAL-85-1	GDSC2	6.0803	8.3075	2.5865	0.6482
T-47D	GDSC2	6.1664	8.5668	2.525	0.7826
CAL-120	GDSC2; CTRP2	7.9328	9.2747	6.5339	0.8296
HMC-1-8	CTRP2	7.9869	9.4252	6.4976	0.9031
CAMA-1	GDSC2; CTRP2	8.3693	10.4493	6.2585	1.3672
CAL-148	GDSC2; CTRP2	8.7473	10.2292	6.5293	0.3366
MCF-7	GDSC2; CTRP2	8.7509	11.0381	6.2063	1.2113
HCC1143	GDSC2; CTRP2	8.8227	12.0225	5.8154	2.4836
HCC1937	GDSC2; CTRP2	8.8974	11.4182	6.1204	1.3673
HDQ-P1	GDSC2; CTRP2	9.046	11.4608	6.1767	1.0822
JIMT-1	GDSC2; CTRP2	9.0713	10.3258	6.6188	0.1041
CAL-51	GDSC2; CTRP2	9.1424	10.6197	6.5421	0.1881
MDA-MB-231	GDSC2; CTRP2	9.4257	11.2547	6.4225	0.3019
HCC1806	GDSC2; CTRP2	9.4851	10.8419	6.5887	0.0758
HCC1954	GDSC2; CTRP2	9.5246	11.1345	6.5026	0.1585
HCC1395	GDSC2; CTRP2	9.7648	11.37	6.5075	0.1131
ZR-75-1	CTRP2	11.085	44.4193	-8.4076	32.1647

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	8.4028	9.4249	6.6881	0.1561

Cancer Drug Sensitivity Data Curated from 62 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
D-542MG	GDSC2	3.9739	5.8745	2.5396	3.3478
D-247MG	GDSC2	4.4966	8.0947	1.8293	6.5134
D-423MG	GDSC2	4.5512	7.2053	2.284	3.7389
PFSK-1	GDSC2	4.8357	6.8742	2.5923	1.6632
D-263MG	GDSC2	4.8829	7.0319	2.5496	1.8116
U-118MG	GDSC2	4.9047	7.3269	2.4339	2.361
CAS-1	GDSC2	4.9769	6.3948	2.8503	0.4801
YKG-1	GDSC2	4.9939	6.3416	2.877	0.3904
D-392MG	GDSC2	5.0087	6.9537	2.6448	1.232
KINGS-1	GDSC2	5.0612	7.1374	2.5948	1.3968
SF268	GDSC2	5.0758	7.7513	2.3416	2.5965
D283 Med	GDSC2	5.0875	6.3748	2.9016	0.2819
U-251MG	GDSC2	5.1364	6.6656	2.8143	0.497
MOG-G-CCM	GDSC2	5.1948	7.57	2.481	1.7664
GI-1	GDSC2	5.2291	7.6795	2.4524	1.86
DK-MG	GDSC2	5.3073	6.7635	2.8462	0.3244
H4	GDSC2	5.3294	7.2467	2.6744	0.8362
Hs 683	GDSC2	5.3377	6.4985	2.95	0.1155
YH-13	GDSC2	5.338	6.8828	2.8149	0.3901
SK-MG-1	GDSC2	5.3468	7.6171	2.5354	1.3667
M059J	GDSC2	5.4333	7.5269	2.6109	0.9897
Becker	GDSC2	5.4989	7.0259	2.8252	0.2977
T98G	GDSC2	5.503	7.4241	2.6805	0.6958
KNS-42	GDSC2	5.6209	13.4647	0.0151	13.9863
KNS-81-FD	GDSC2	5.6261	7.8291	2.5778	0.963
MOG-G-UVW	GDSC2	5.6331	7.6968	2.6316	0.7722
A-172	GDSC2	5.7262	7.3751	2.7867	0.2998
42-MG-BA	GDSC2	5.7568	7.4709	2.7642	0.3379
LN-405	GDSC2	5.7939	7.2675	2.8487	0.1667
SF539	GDSC2	5.8628	7.4695	2.8038	0.2238
Onda 10	GDSC2	5.8714	7.4352	2.8188	0.196
SW1783	GDSC2	5.8995	7.851	2.6822	0.4764
D-566MG	GDSC2	5.9302	8.0961	2.6043	0.6779
8-MG-BA	GDSC2	5.9321	7.3359	2.8737	0.1069
KS-1 [Human Krukenberg tumour]	GDSC2	5.9395	8.3343	2.5182	0.9481
Onda 11	GDSC2	5.9752	7.8743	2.703	0.3936
SNB-75	GDSC2	6.1093	8.3032	2.5997	0.5963
D-502MG	GDSC2	6.1267	7.9757	2.7237	0.2961
D-336MG	GDSC2	6.5547	8.598	2.6631	0.2842
KNS-81	CTRP2	6.5896	20.2383	-0.6035	24.8052
D-245MG	GDSC2	6.637	9.2684	2.4548	0.7317
KNS-60	CTRP2	6.8782	16.6855	1.4017	18.1581
SNU-738	CTRP2	7.4459	8.8886	6.4143	1.8522
SNU-626	CTRP2	7.5417	8.9337	6.4571	1.5466
SF295	GDSC2; CTRP2	7.9828	10.5628	5.9743	2.8709
SNU-466	CTRP2	8.0005	9.2681	6.5718	0.6501
LN-18	GDSC2; CTRP2	8.3261	9.3739	6.6766	0.2008
NMC-G1	GDSC2; CTRP2	8.458	9.8475	6.5522	0.4158
U-87MG ATCC	GDSC2; CTRP2	8.601	9.9343	6.5797	0.2903
SNU-1105	CTRP2	8.7652	9.9816	6.6269	0.1556
SNU-489	CTRP2	8.7692	9.8167	6.6859	0.0806
GaMG	GDSC2; CTRP2	8.9865	11.3856	6.1787	1.1183
SNU-201	CTRP2	9.0751	10.1867	6.6673	0.058
AM-38	GDSC2; CTRP2	9.1381	10.7991	6.4757	0.2989
Daoy	GDSC2; CTRP2	9.2361	11.2945	6.3299	0.5637
SF126	GDSC2; CTRP2	9.2488	10.9761	6.4547	0.3008
SW1088	GDSC2; CTRP2	9.3633	11.3946	6.3455	0.4729
GB-1	GDSC2; CTRP2	9.508	10.8158	6.6052	0.0607
LN-229	GDSC2; CTRP2	9.5624	11.193	6.496	0.1593
DBTRG-05MG	GDSC2; CTRP2	9.5875	11.2695	6.4785	0.1764
ONS-76	GDSC2; CTRP2	9.7066	11.0819	6.5842	0.0571
KALS-1	GDSC2; CTRP2	12.2924	21.1231	3.7286	6.2386

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TGBC1TKB	GDSC2	4.672	6.6266	2.6128	1.7694
ETK-1	GDSC2	4.8233	8.5376	1.834	5.8265
TGBC24TKB	GDSC2	5.0687	7.5137	2.4405	2.1106

Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
EN	GDSC2	5.1618	8.6683	1.9818	4.3845
MFE-319	GDSC2	5.2192	6.7796	2.8055	0.4764
ESS-1	GDSC2	5.5911	7.2264	2.7886	0.346
AN3-CA	GDSC2	5.886	12.8015	0.5109	10.9938
MFE-296	GDSC2	6.1886	7.676	2.8478	0.0977
MFE-280	GDSC2	6.2132	9.8602	2.0321	2.6816
HEC-265	CTRP2	8.4206	10.0637	6.4485	0.717
JHUEM-2	CTRP2	8.6064	10.3881	6.4047	0.7192
HEC-6	CTRP2	8.6117	9.9888	6.5636	0.3194
HEC-59	CTRP2	8.6753	10.7063	6.3074	0.9561
HEC-251	CTRP2	8.7268	10.1431	6.5531	0.296
RL95-2	GDSC2; CTRP2	8.7816	10.527	6.4295	0.5506
HEC-108	CTRP2	8.8556	11.9682	5.8585	2.2951
EFE-184	CTRP2	8.9328	10.6484	6.4481	0.4335
HEC-151	CTRP2	8.9533	10.4039	6.5473	0.2308
HEC-1-B	CTRP2	8.9723	10.7885	6.4112	0.4993
KLE	GDSC2; CTRP2	9.0104	11.5624	6.1169	1.2894
HEC-50B	CTRP2	10.0018	11.7319	6.4677	0.1184
Ishikawa (Heraklio) 02 ER-	CTRP2	8.0658	9.3869	6.5548	0.6531

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RCC10RGB	GDSC2	4.4671	7.1944	2.2366	4.1668
KTCTL-13	GDSC2	4.8091	6.939	2.5508	1.8994
TK-10	GDSC2	4.8749	8.0549	2.0903	4.2671
ACHN	GDSC2	4.9339	6.71	2.7084	1.0353
KTCTL-140	GDSC2	4.9666	7.9347	2.1992	3.5118
A-704	GDSC2	4.9764	8.1442	2.1102	3.9838
BB65-RCC	GDSC2	4.9995	11.8777	0.3487	13.7187
A-498	GDSC2	5.1028	6.679	2.7954	0.5774
KTCTL-195	GDSC2	5.1651	7.4531	2.5151	1.6432
SW13	GDSC2	5.193	7.256	2.6092	1.2041
VMRC-RCZ	GDSC2	5.32	7.4499	2.5902	1.1657
KMRC-1	GDSC2	5.3286	6.7244	2.8683	0.2651
SW156	GDSC2	5.3354	7.8287	2.443	1.7837
LB996-RCC	GDSC2	5.4958	7.5637	2.6239	0.8941
CAL-54	GDSC2	5.5119	7.8636	2.5131	1.3052
786-O	GDSC2	5.6586	7.5261	2.7061	0.5288
KTCTL-21	GDSC2	5.6655	8.5944	2.2878	2.1259
UO-31	GDSC2	5.7198	7.5253	2.7304	0.4339
KTCTL-26A	GDSC2	5.7205	7.4906	2.7433	0.4016
SN12C	GDSC2	5.748	7.4857	2.7556	0.361
NCC010	GDSC2	5.9226	8.1375	2.5857	0.7389
KTCTL-1M	GDSC2	5.9918	8.0083	2.6611	0.4888
NCC021	GDSC2	6.0409	8.0079	2.6802	0.4209
HA7-RCC	GDSC2	6.2237	8.5661	2.5485	0.6812
LB2241-RCC	GDSC2	6.3119	8.3165	2.6725	0.339
RXF 393L	GDSC2	6.5999	8.8968	2.5749	0.4463
Caki-1	GDSC2	6.8801	14.1739	0.4965	9.2459
LB1047-RCC	GDSC2	6.9096	9.0812	2.6239	0.2595
BFTC-909	GDSC2; CTRP2	8.2963	9.8703	6.4678	0.7477
TUHR10TKB	CTRP2	8.5659	9.5968	6.6885	0.1148
OS-RC-2	GDSC2; CTRP2	8.8774	10.7806	6.3726	0.6433
SNU-1272	CTRP2	8.9228	12.3323	5.734	2.6734
769-P	GDSC2; CTRP2	8.9733	10.9388	6.3532	0.6402
TUHR4TKB	CTRP2	9.0997	10.5128	6.564	0.1668
VMRC-RCW	GDSC2; CTRP2	9.6961	11.2482	6.5248	0.1061
KMRC-20	GDSC2; CTRP2	9.8017	11.2431	6.5629	0.063

Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-C1	GDSC2	4.5822	6.6975	2.5327	2.3097
SW948	GDSC2	4.6166	9.7768	1.0995	10.5298
SW1116	GDSC2	4.8676	6.5285	2.7506	0.9232
HCT 15	GDSC2	4.923	6.7211	2.6988	1.0857
NCI-H747	GDSC2	5.256	7.7632	2.4308	1.9297
SNU-283	GDSC2	5.3256	7.1676	2.7033	0.7375
GP5d	GDSC2	5.3839	7.2396	2.7005	0.7073
RCM-1 [Human ESC]	GDSC2	5.4345	7.1691	2.748	0.5273
LS1034	GDSC2	5.4517	7.0518	2.7979	0.3822
SW837	GDSC2	5.5384	7.3084	2.7382	0.5003
COLO 320HSR	GDSC2	5.6088	7.0317	2.8636	0.1875
NCI-H716	GDSC2	5.6488	7.2844	2.7898	0.3209
COLO 678	GDSC2	5.6767	7.4148	2.7537	0.3945
T84	GDSC2	5.7627	7.6251	2.7109	0.4649
SW1417	GDSC2	5.8536	7.4009	2.8242	0.1915
CaR-1	GDSC2	5.9024	7.9963	2.6301	0.6173
SW626	GDSC2	5.9736	8.0943	2.6225	0.6018
SNU-C2B	GDSC2	5.9947	8.6191	2.432	1.2148
DiFi	GDSC2	6.1149	8.0466	2.6944	0.3606
HCC2998	GDSC2	6.3447	8.2279	2.7154	0.2492
C2BBe1	GDSC2	6.4814	8.2325	2.762	0.1504
SNU-81	GDSC2; CTRP2	7.8601	9.5424	6.3731	1.479
SNU-61	GDSC2; CTRP2	8.0529	10.4327	6.0804	2.3654
DLD-1	CTRP2	8.2727	9.5766	6.576	0.4555
OUMS-23	CTRP2	8.3835	9.4723	6.6632	0.206
HCT 116	GDSC2; CTRP2	8.4165	9.9985	6.4732	0.6488
LS411N	GDSC2; CTRP2	8.4188	9.5536	6.6474	0.2238
HT-55	GDSC2; CTRP2	8.5185	9.9554	6.5367	0.4227
HT-29	GDSC2; CTRP2	8.6356	9.9578	6.585	0.2666
KM12	GDSC2; CTRP2	8.7213	11.019	6.1993	1.2574
COLO205	GDSC2; CTRP2	8.7243	10.2906	6.4962	0.419
SK-CO-1	GDSC2; CTRP2	8.778	10.5074	6.4356	0.5373
NCI-H508	GDSC2; CTRP2	8.8037	10.138	6.5855	0.2106
SNU-C5	GDSC2; CTRP2	8.8412	10.5566	6.4442	0.4849
CCK-81	GDSC2; CTRP2	8.8551	11.3337	6.1345	1.3564
COLO201	CTRP2	8.9373	10.2241	6.6054	0.1461
SW48	GDSC2; CTRP2	8.9574	10.5695	6.488	0.3391
LS180	GDSC2; CTRP2	9.0014	10.6986	6.4578	0.3838
MDST8	GDSC2; CTRP2	9.0336	10.0158	6.71	0.0331
HT115	GDSC2; CTRP2	9.042	10.1717	6.661	0.067
RKO	GDSC2; CTRP2	9.1131	17.5655	3.3752	11.4756
SNU-175	GDSC2; CTRP2	9.218	10.6176	6.5708	0.1336
LS123	GDSC2; CTRP2	9.2416	10.8	6.5154	0.2032
CL-11	GDSC2; CTRP2	9.2694	11.2008	6.3796	0.4393
CW-2	GDSC2; CTRP2	9.3442	12.1006	6.058	1.2242
LS513	CTRP2	9.4434	10.8475	6.5722	0.0956
SW620	GDSC2; CTRP2	9.4762	11.0731	6.5063	0.1633
SW1463	GDSC2; CTRP2	9.4832	11.0544	6.5153	0.1507
LoVo	GDSC2; CTRP2	9.6007	11.481	6.4084	0.2746
SNU-407	GDSC2; CTRP2	9.635	11.6648	6.3551	0.3549
SNU-C2A	CTRP2	10.2904	12.3134	6.3711	0.1744

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC2	5.5701	7.392	2.7201	0.5352

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHH-6	GDSC2	4.2969	6.5049	2.451	3.2408
HuH-1	GDSC2	4.4364	6.3451	2.6071	2.1328
SK-HEP-1	GDSC2	4.6392	7.389	2.2531	3.7586
JHH-1	GDSC2	4.9056	6.1369	2.9171	0.3237
Hep-G2/C3A	GDSC2	5.009	6.3471	2.881	0.3714
JHH-7	GDSC2	5.092	6.85	2.7247	0.8339
SNU-449	GDSC2	5.1047	7.8074	2.3328	2.6017
SNU-423	GDSC2	5.3108	6.996	2.7622	0.555
Huh-7	GDSC2	5.5192	7.1717	2.7806	0.3958
JHH-2	GDSC2	5.7254	7.653	2.686	0.551
HLE	GDSC2	5.782	7.6737	2.7008	0.4824
JHH-4	GDSC2	5.8224	7.5309	2.7675	0.307
SNU-387	GDSC2	5.9864	8.0881	2.6298	0.5746
SNU-761	CTRP2	6.7165	14.0997	2.5623	14.0764
HuH-6	CTRP2	7.831	10.1688	6.0613	2.7301
Hep 3B2.1-7	GDSC2; CTRP2	8.502	10.1616	6.4474	0.6663
SNU-878	CTRP2	8.5759	10.0769	6.5146	0.4474
Hep-G2	CTRP2	8.8869	10.423	6.5139	0.3139
SNU-886	CTRP2	8.8899	10.5884	6.4528	0.509
Li-7	CTRP2	9.0692	11.1559	6.3106	0.6964
SNU-398	GDSC2; CTRP2	9.3433	11.4429	6.3188	0.5398
SNU-182	CTRP2	9.5978	12.1098	6.1714	0.7642

Cancer Drug Sensitivity Data Curated from 201 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COR-L279	GDSC2	3.959	6.5458	2.2051	5.4185
NCI-H1963	GDSC2	3.9809	7.6265	1.691	8.5336
HCC33	GDSC2	4.1017	6.4369	2.3566	4.1814
NCI-H841	GDSC2	4.156	6.8819	2.1799	5.1332
Ms-1	GDSC2	4.1844	6.6178	2.3255	4.197
COR-L88	GDSC2	4.2336	6.9321	2.2084	4.7967
NCI-H2135	GDSC2	4.4092	8.0586	1.787	6.9538
COR-L321	GDSC2	4.4355	6.2156	2.6639	1.8334
BEN	GDSC2	4.4437	6.6864	2.4571	2.9458
NCI-H2373	GDSC2	4.5277	6.5041	2.5879	2.0981
IST-SL1	GDSC2	4.54	8.6192	1.6069	7.7415
DMS 273	GDSC2	4.5656	6.5729	2.5785	2.0922
NCI-H345	GDSC2	4.5778	5.7819	2.9151	0.5295
NCI-H1869	GDSC2	4.5957	7.7894	2.0396	5.0702
NCI-H2795	GDSC2	4.6502	6.8557	2.5007	2.3778
NCI-H1975	GDSC2	4.6531	8.1105	1.9254	5.6264
KNS-62	GDSC2	4.6571	8.0796	1.9425	5.5181
IA-LM	GDSC2	4.679	6.8352	2.5258	2.2039
NCI-H250	GDSC2	4.7393	8.7519	1.6779	6.902
NCI-H209	GDSC2	4.7513	6.9169	2.5295	2.0837
NCI-H1876	GDSC2	4.7539	6.796	2.5832	1.81
VMRC-LCD	GDSC2	4.8179	12.5809	-0.1277	16.5011
IST-SL2	GDSC2	4.8312	7.1753	2.4601	2.3289
NCI-H1105	GDSC2	4.857	7.3168	2.4122	2.5404
NCI-H2170	GDSC2	4.8674	7.2702	2.4384	2.3899
Lu-65	GDSC2	4.8942	7.026	2.5579	1.757
NCI-H82	GDSC2	4.8999	6.2837	2.8602	0.4959
SBC-3	GDSC2	4.9175	7.1124	2.5332	1.848
NCI-H1437	GDSC2	4.9262	7.3384	2.4405	2.2979
NCI-H1573	GDSC2	4.9315	7.4206	2.4076	2.4588
COR-L105	GDSC2	4.9357	8.9559	1.7095	6.3271
NCI-H1693	GDSC2	4.9567	7.2048	2.5141	1.8918
CPC-N	GDSC2	4.9621	7.851	2.2342	3.3292
COR-L303	GDSC2	4.9923	6.6549	2.7569	0.7923
NCI-H2722	GDSC2	5.0028	7.1605	2.5564	1.6358
NCI-H1688	GDSC2	5.0252	7.6161	2.3731	2.5055
NCI-H2141	GDSC2	5.0474	6.7709	2.7359	0.8273
NCI-H810	GDSC2	5.057	7.509	2.4364	2.1458
NCI-H1770	GDSC2	5.0623	8.0468	2.2038	3.3379
NCI-H847	GDSC2	5.0679	6.8489	2.7144	0.8929
PaCa-3	GDSC2	5.0813	10.4432	1.0993	9.5048
NCI-H522	GDSC2	5.0873	7.4849	2.4624	1.981
NCI-H740	GDSC2	5.0993	8.7083	1.9263	4.7974
COR-L32	GDSC2	5.1252	8.0986	2.2163	3.1771
NCI-H1836	GDSC2	5.1328	7.1479	2.6247	1.1965
LC-1/sq	GDSC2	5.1375	7.7111	2.3919	2.2619
NCI-H1563	GDSC2	5.1423	6.7523	2.7841	0.589
Lu-165	GDSC2	5.1519	6.475	2.8903	0.2827
NCI-H2227	GDSC2	5.1545	7.2948	2.5752	1.3864
NCI-H2081	GDSC2	5.1651	7.3695	2.5496	1.488
NCI-H322M	GDSC2	5.179	9.3259	1.6903	5.9792
NCI-H1048	GDSC2	5.1848	6.7725	2.7942	0.5306
NCI-H1781	GDSC2	5.1854	6.7895	2.788	0.5495
COR-L23	GDSC2	5.2035	6.8551	2.7708	0.5933
NCI-H2369	GDSC2	5.2087	6.6848	2.8363	0.3947
LK-2	GDSC2	5.2095	7.1968	2.6406	1.0614
NCI-H720	GDSC2	5.2213	6.4853	2.9127	0.2087
NCI-H64	GDSC2	5.2257	6.8374	2.7866	0.5297
DMS 53	GDSC2	5.2567	7.5111	2.5357	1.4545
NCI-H2171	GDSC2	5.263	6.5348	2.9107	0.1997
NCI-H2196	GDSC2	5.2809	6.744	2.843	0.3436
NCI-H146	GDSC2	5.2933	7.0157	2.7475	0.6117
NCI-H1341	GDSC2	5.298	7.0112	2.7511	0.5973
NCI-H2461	GDSC2	5.3224	8.7498	2.0381	3.8244
NCI-H1703	GDSC2	5.3521	7.5223	2.576	1.194
LB647-SCLC	GDSC2	5.3601	7.4698	2.6006	1.0894
NCI-H524	GDSC2	5.3644	7.1854	2.713	0.6789
NCI-H838	GDSC2	5.3727	6.7445	2.8776	0.2303
NCI-H2591	GDSC2	5.4052	8.9799	1.9826	3.9935
NCI-H3255	GDSC2	5.4118	7.2739	2.6993	0.6932
NCI-H596	GDSC2	5.4383	7.3153	2.6947	0.6911
NCI-H2804	GDSC2	5.4582	8.938	2.031	3.6593
NCI-H1092	GDSC2	5.5045	7.0552	2.8169	0.3144
SBC-1	GDSC2	5.5122	7.2178	2.7611	0.4504
NCI-H1436	GDSC2	5.5354	7.3678	2.715	0.5691
NCI-H510A	GDSC2	5.5414	7.3918	2.7085	0.5851
NCI-H835	GDSC2	5.5433	14.9875	-0.7792	17.7157
NCI-H2029	GDSC2	5.545	7.0865	2.821	0.29
NCI-H290	GDSC2	5.5705	7.8398	2.5491	1.113
NCI-H1734	GDSC2	5.5718	8.0122	2.4811	1.3808
NCI-H1793	GDSC2	5.5799	9.4522	1.8712	4.3167
Lu-135	GDSC2	5.5905	7.2523	2.7791	0.3689
RERF-LC-Sq1	GDSC2	5.609	8.7911	2.1761	2.7206
UMC-11	GDSC2	5.6533	7.3825	2.7564	0.398
NCI-H2066	GDSC2	5.7038	7.3849	2.7748	0.334
RERF-LC-KJ	GDSC2	5.707	7.1182	2.869	0.1553
DMS 114	GDSC2	5.7711	7.4214	2.7871	0.2837
HOP-62	GDSC2	5.7753	7.5527	2.742	0.382
EMC-BAC-2	GDSC2	5.792	7.7655	2.6711	0.5585
NCI-H2803	GDSC2	5.8097	7.6472	2.7212	0.4178
NCI-H647	GDSC2	5.8146	7.7032	2.7028	0.462
COLO 668	GDSC2	5.8334	7.9355	2.6248	0.6713
A-427	GDSC2	5.8351	16.5822	-1.3483	19.3283
NCI-H1568	GDSC2	5.8455	7.8904	2.6464	0.6007
NCI-H2818	GDSC2	5.8512	7.9985	2.6085	0.7107
LC-2/ad	GDSC2	5.8667	8.2401	2.5232	0.9818
NCI-H1993	GDSC2	5.9012	7.5425	2.7924	0.2336
ChaGo-K-1	GDSC2	5.9235	8.1571	2.5787	0.7602
NCI-H513	GDSC2	5.9966	7.9109	2.698	0.3968
NCI-H2869	GDSC2	5.9999	7.8952	2.7049	0.3797
SK-MES-1	GDSC2	6.0049	7.7244	2.7669	0.2507
Lu-99A	GDSC2	6.0069	8.7987	2.3667	1.4542
NCI-H1944	GDSC2	6.0431	8.2984	2.5749	0.7023
NCI-H2595	GDSC2	6.0669	7.7689	2.7739	0.2216
NCI-H2810	GDSC2	6.0785	8.4441	2.5349	0.8041
Lu-134-A	GDSC2	6.0812	8.4583	2.5306	0.8158
SW1573	GDSC2	6.1011	8.1979	2.6349	0.5069
NCI-H1694	GDSC2	6.1017	7.6977	2.8106	0.157
NCI-H1915	GDSC2	6.1159	7.9821	2.7175	0.3119
NCI-H2731	GDSC2	6.1161	8.1698	2.6509	0.4604
NCI-H1623	GDSC2	6.1274	7.9743	2.7245	0.2944
NCI-H23	GDSC2	6.1561	8.003	2.725	0.2847
NCI-H1651	GDSC2	6.1626	7.9475	2.7467	0.2432
EMC-BAC-1	GDSC2	6.1765	8.6394	2.5019	0.8484
NCI-H2110	GDSC2	6.1955	19.3634	-2.4482	22.3043
NCI-H2347	GDSC2	6.2026	8.2535	2.6538	0.4184
HOP-92	GDSC2	6.2043	8.3923	2.6045	0.5381
COR-L311	GDSC2	6.2457	8.4517	2.5991	0.5332
NCI-H748	GDSC2	6.2512	8.2377	2.6777	0.3486
NCI-H2342	GDSC2	6.2761	8.3396	2.651	0.3971
RERF-LC-MS	GDSC2	6.2806	7.6626	2.8831	0.0569
ABC-1	GDSC2	6.4274	8.7216	2.5719	0.522
EKVX	GDSC2	6.4422	8.6878	2.5897	0.4732
NCI-H1648	GDSC2	6.5667	8.6023	2.6659	0.2759
NCI-H3122	GDSC2	6.6899	8.6927	2.6789	0.2245
NCI-H2228	GDSC2; CTRP2	7.2456	11.7493	4.1204	6.4809
NCI-H2444	GDSC2; CTRP2	7.3039	8.7849	5.5271	0.6924
PC-14	GDSC2; CTRP2	7.3992	15.4966	2.3944	13.4665
NCI-H1581	GDSC2; CTRP2	7.5905	9.3303	6.3007	2.1045
DMS 79	GDSC2; CTRP2	7.6339	9.3684	6.3115	2.001
Sq-1	CTRP2	7.6551	14.0029	4.0444	11.3048
MOR/CPR	CTRP2	7.6664	9.0686	6.4732	1.3264
RERF-LC-Ad1	CTRP2	7.761	9.2318	6.4557	1.2825
NCI-H1184	CTRP2	7.8959	14.9322	3.7698	11.97
NCI-H69	GDSC2; CTRP2	8.053	9.9016	6.3239	1.449
NCI-H2291	GDSC2; CTRP2	8.0588	10.6006	6.0056	2.6487
NCI-H2122	GDSC2; CTRP2	8.2451	11.0602	5.9087	2.7913
SBC-5	GDSC2; CTRP2	8.3961	9.4401	6.68	0.1716
NCI-H520	GDSC2; CTRP2	8.4059	11.3699	5.8649	2.7645
NCI-H526	GDSC2; CTRP2	8.4145	10.4299	6.2912	1.2159
SW1271	GDSC2; CTRP2	8.4328	17.5418	2.144	12.6642
HCC1588	CTRP2	8.4497	10.3613	6.3388	1.0311
Calu-3	GDSC2; CTRP2	8.4807	10.7392	6.1925	1.4898
NCI-H2126	CTRP2	8.4962	9.9726	6.5202	0.4751
SK-LU-1	GDSC2; CTRP2	8.606	13.2597	5.1043	5.4844
NCI-H226	GDSC2; CTRP2	8.6516	19.7184	1.2396	15.5328
LOU-NH91	GDSC2; CTRP2	8.7233	10.9571	6.2265	1.1695
LCLC-103H	GDSC2; CTRP2	8.7573	9.997	6.6184	0.1704
NCI-H2286	CTRP2	8.7596	10.0284	6.608	0.1862
NCI-H196	GDSC2; CTRP2	8.838	10.0423	6.6325	0.1312
Lu-99	CTRP2	8.8445	10.7884	6.3545	0.71
NCI-H460	GDSC2; CTRP2	8.8705	10.6653	6.4147	0.541
SHP-77	GDSC2; CTRP2	8.8749	10.1079	6.6232	0.1358
NCI-H1666	GDSC2; CTRP2	8.8997	12.4481	5.6683	2.9385
NCI-H292	GDSC2; CTRP2	8.9393	10.5918	6.4723	0.3785
NCI-H1755	GDSC2; CTRP2	8.9615	10.657	6.4568	0.4021
NCI-H2087	GDSC2; CTRP2	8.9777	12.0583	5.8867	2.0767
NCI-H889	CTRP2	9.0155	11.5252	6.135	1.2297
LCLC-97TM1	GDSC2; CTRP2	9.0218	12.1182	5.8846	2.0426
HCC1833	CTRP2	9.065	11.3859	6.2165	0.954
LXF 289	GDSC2; CTRP2	9.0732	10.9615	6.388	0.5056
NCI-H446	GDSC2; CTRP2	9.0765	10.8999	6.413	0.4484
NCI-H1373	CTRP2	9.0976	10.9942	6.3859	0.4993
HCC1195	CTRP2	9.1028	10.7649	6.4743	0.3134
NCI-H2085	GDSC2; CTRP2	9.1119	11.168	6.3249	0.6374
NCI-H1792	GDSC2; CTRP2	9.1246	10.8502	6.4515	0.3493
COLO 699	CTRP2	9.133	11.71	6.1162	1.2004
NCI-H2023	GDSC2; CTRP2	9.1344	11.0575	6.3773	0.502
NCI-H1435	GDSC2; CTRP2	9.1441	10.5903	6.5532	0.1718
NCI-H211	GDSC2; CTRP2	9.1583	11.2573	6.3104	0.6489
NCI-H650	GDSC2; CTRP2	9.1816	10.4923	6.6009	0.1055
Calu-6	GDSC2; CTRP2	9.1941	10.6173	6.5622	0.1489
NCI-H2172	GDSC2; CTRP2	9.22	10.5926	6.5802	0.1221
HCC1171	CTRP2	9.2269	12.511	5.8244	2.0596
NCI-H2106	CTRP2	9.2605	10.9731	6.4603	0.2871
HCC827	GDSC2; CTRP2	9.2754	10.7677	6.5394	0.1617
NCI-H1155	GDSC2; CTRP2	9.2874	10.873	6.5067	0.2048
NCI-H358	GDSC2; CTRP2	9.2992	10.9542	6.4822	0.2394
HCC95	CTRP2	9.3527	10.6908	6.5937	0.0878
HARA [Human squamous cell lung carcinoma]	GDSC2; CTRP2	9.369	10.8589	6.5418	0.1402
NCI-H1650	GDSC2; CTRP2	9.3977	13.9752	5.2693	3.8622
EBC-1	GDSC2; CTRP2	9.4143	11.0779	6.4816	0.2106
NCI-H727	GDSC2; CTRP2	9.4186	11.3339	6.3907	0.3616
HCC78	GDSC2; CTRP2	9.4333	11.1316	6.4697	0.2236
HCC2108	CTRP2	9.44	10.9983	6.5191	0.1544
HCC366	GDSC2; CTRP2	9.4774	11.2954	6.4278	0.2776
NCI-H441	GDSC2; CTRP2	9.49	11.1059	6.4999	0.1687
NCI-H2009	GDSC2; CTRP2	9.5246	11.0479	6.5325	0.1239
NCI-H1838	GDSC2; CTRP2	9.5535	11.2313	6.4793	0.1823
HCC2279	CTRP2	9.6361	12.6776	5.9619	1.3048
RERF-LC-A1	CTRP2	9.6863	11.0092	6.6014	0.0479
A-549	GDSC2; CTRP2	9.6993	11.3801	6.4807	0.1523
NCI-H2030	GDSC2; CTRP2	9.7132	11.4816	6.4504	0.1868
NCI-H661	GDSC2; CTRP2	9.7313	17.6703	3.7516	9.169
NCI-H1355	GDSC2; CTRP2	9.7401	11.3499	6.5056	0.1185
NCI-H1299	GDSC2; CTRP2	9.8707	11.7995	6.397	0.2245
HCC44	GDSC2; CTRP2	9.8752	12.1228	6.2823	0.4083
HCC15	GDSC2; CTRP2	9.9575	11.4457	6.5485	0.0591
EPLC-272H	GDSC2; CTRP2	10.114	23.2675	1.31	16.8144
NCI-H2405	GDSC2; CTRP2	10.18	12.2113	6.3665	0.1999
CAL-12T	GDSC2; CTRP2	10.4052	19.4869	3.3336	9.7755

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC2	4.7167	7.0257	2.4627	2.4804

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHOS-4	GDSC2	3.837	6.6762	2.0523	6.6558
OV56	GDSC2	3.9795	6.2615	2.3575	4.4379
OAW42	GDSC2	4.9315	6.6104	2.7472	0.8804
JHOS-2	GDSC2	5.0187	7.0516	2.6095	1.3763
OC 314	GDSC2	5.0308	6.376	2.8791	0.3658
TOV-21G	GDSC2	5.0778	7.1114	2.6134	1.2981
OVCAR-3	GDSC2	5.12	7.4842	2.4794	1.8604
EFO-21	GDSC2	5.2408	10.8617	1.0064	9.6855
ES-2	GDSC2	5.5238	6.9681	2.8548	0.2276
OV-90	GDSC2	5.6005	7.7982	2.5787	0.9791
EFO-27	GDSC2	5.6489	12.4254	0.5329	11.3589
OVKATE	GDSC2	5.7181	7.5626	2.7162	0.4717
Caov-4	GDSC2	5.7933	8.4127	2.4229	1.4173
TOV-112D	GDSC2	5.9024	7.6191	2.7661	0.2832
OVCAR-5	GDSC2	6.0686	7.9858	2.6986	0.3681
ES2	CTRP2	8.3242	11.1545	5.9141	2.6741
OVK18	GDSC2; CTRP2	8.9408	10.6034	6.4685	0.3859
SK-OV-3	GDSC2; CTRP2	8.9635	10.3451	6.5723	0.1877
OVISE	GDSC2; CTRP2	8.9642	10.1779	6.6313	0.1083
DOV13	GDSC2; CTRP2	8.9889	10.7815	6.4211	0.4691
SNU-8	CTRP2	8.9957	10.0204	6.6958	0.045
Caov-3	GDSC2; CTRP2	8.998	10.3113	6.5972	0.144
IGROV-1	GDSC2; CTRP2	9.0123	10.8807	6.393	0.5229
OVSAHO	CTRP2	9.0316	11.0236	6.3458	0.6274
SNU-119	CTRP2	9.0332	10.9258	6.3846	0.5327
FU-OV-1	GDSC2; CTRP2	9.1442	10.9177	6.4343	0.3762
ONCO-DG-1	CTRP2	9.2656	10.5296	6.6178	0.0772
HEY A8	CTRP2	9.28	10.2911	6.7017	0.0227
JHOC-5	CTRP2	9.2972	10.7576	6.5509	0.1427
A2780	GDSC2; CTRP2	9.3318	14.5984	4.9424	5.1694
SNU-840	CTRP2	9.529	11.2492	6.4639	0.2088
OVTOKO	GDSC2; CTRP2	9.5656	11.0827	6.5352	0.1146
RMG-I	GDSC2; CTRP2	9.62	11.98	6.2311	0.6129
TYK-nu	GDSC2; CTRP2	9.7022	11.3713	6.4848	0.147
OVCAR-8	GDSC2; CTRP2	9.7541	11.554	6.4401	0.1918
MCAS	CTRP2	9.7687	11.4269	6.4894	0.1309
Kuramochi	GDSC2; CTRP2	9.8219	11.4047	6.5157	0.0978
OAW28	GDSC2; CTRP2	9.9963	12.264	6.2784	0.3764
OVCAR-4	GDSC2; CTRP2	10.0251	11.9939	6.3857	0.2064

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Panc 03.27	GDSC2	4.5722	8.0338	1.9088	5.8857
SW1990	GDSC2	4.6098	7.6955	2.0926	4.7343
PaTu 8988t	GDSC2	4.9041	6.8861	2.6218	1.4451
Panc 10.05	GDSC2	4.9492	7.2417	2.4944	1.9977
HuP-T3	GDSC2	5.1914	7.1797	2.6391	1.0833
KP-2	GDSC2	5.235	6.7344	2.8285	0.403
Panc 08.13	GDSC2	5.2889	7.5318	2.5426	1.3923
MIA PaCa-2	GDSC2	5.4082	7.3455	2.6703	0.7936
DAN-G	GDSC2	5.4214	6.827	2.8666	0.2367
Hs 766T	GDSC2	5.4598	12.5907	0.3255	12.8106
Capan-2	GDSC2	5.5293	8.1906	2.3882	1.8205
PL4	GDSC2	5.6604	7.6427	2.6634	0.6536
PSN1	GDSC2	5.703	7.4742	2.7424	0.4112
AsPC-1	GDSC2	5.7032	12.8012	0.3898	11.9743
Capan-1	GDSC2	5.8744	7.6661	2.7391	0.35
KP-1N	GDSC2	5.9718	8.3296	2.5337	0.8747
Panc 04.03	GDSC2	6.1909	7.9339	2.7615	0.2111
Panc 02.03	GDSC2	6.2253	7.9514	2.7677	0.1933
MZ-PC-1	GDSC2	6.4252	8.4019	2.6842	0.2823
SU.86.86	GDSC2; CTRP2	7.1633	12.839	3.5285	9.1857
SNU-410	CTRP2	8.1908	11.9307	5.4604	4.6403
YAPC	GDSC2; CTRP2	8.7101	10.271	6.4977	0.4223
QGP-1	GDSC2; CTRP2	8.7923	10.2672	6.5335	0.3103
TCC-Pan2	CTRP2	8.803	10.6452	6.3925	0.6333
SUIT-2	GDSC2; CTRP2	8.8486	10.2678	6.5558	0.2483
PaTu 8902	GDSC2; CTRP2	8.8557	10.2982	6.5475	0.2611
L3.3	CTRP2	8.9531	10.0127	6.6837	0.0583
SNU-213	CTRP2	8.973	15.2335	4.4067	7.7303
Panc 05.04	CTRP2	8.9916	10.2486	6.6168	0.1205
KP-4	GDSC2; CTRP2	9.0461	10.4152	6.5785	0.1589
HPAF-II	GDSC2; CTRP2	9.1677	11.4155	6.2523	0.7926
HPAC	GDSC2; CTRP2	9.1712	11.6438	6.1619	1.0398
CFPAC-1	GDSC2; CTRP2	9.2604	10.779	6.5299	0.1779
PK-59	CTRP2	9.4072	11.4919	6.327	0.4942
BxPC-3	GDSC2; CTRP2	9.4845	11.3409	6.4141	0.2985
KP-3	GDSC2; CTRP2	9.835	11.7336	6.4069	0.2188
HuP-T4	GDSC2; CTRP2	9.9186	11.5571	6.4978	0.1016

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MPP 89	GDSC2	5.1906	7.1494	2.6509	1.0371
IST-Mes1	GDSC2	5.6031	8.5509	2.2748	2.2567
NCI-H2452	GDSC2; CTRP2	8.665	17.5356	2.3089	11.6742
ACC-MESO-1	CTRP2	9.0018	10.162	6.6502	0.0822
NCI-H28	GDSC2; CTRP2	9.5451	11.2098	6.4838	0.1783
NCI-H2052	GDSC2; CTRP2	9.9162	16.3674	4.4849	6.1826
MSTO-211H	GDSC2; CTRP2	10.0493	21.1653	2.287	13.8681

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H660	GDSC2	4.9935	6.351	2.8734	0.4011
VCaP	GDSC2	5.3821	7.1377	2.7383	0.5865
LNCaP clone FGC	GDSC2	5.3998	8.7286	2.0908	3.4325
DU145	GDSC2	5.7256	7.777	2.6399	0.6878
PC-3	GDSC2	6.0548	8.5458	2.4863	0.9777
22Rv1	GDSC2; CTRP2	10.0422	11.812	6.4546	0.1254

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC2	5.6111	7.4262	2.7239	0.5032
YD-15	CTRP2	8.812	9.7296	6.73	0.0382

Cancer Drug Sensitivity Data Curated from 63 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
GAK	GDSC2	3.7779	5.3561	2.6552	3.0653
UACC-62	GDSC2	3.7868	5.3673	2.656	3.0412
VMRC-MELG	GDSC2	4.4532	6.219	2.6721	1.7652
IGR-37	GDSC2	4.5297	6.26	2.6954	1.5438
A2058	GDSC2	4.5665	5.7428	2.9253	0.5015
Hs 940.T	GDSC2	4.5829	9.5198	1.2006	10.0264
SK-MEL-2	GDSC2	4.7589	6.0198	2.9012	0.4524
HT-144	GDSC2	4.8993	6.7259	2.6856	1.1657
WT2-iPS	GDSC2	4.9026	6.2608	2.87	0.4631
SK-MEL-3	GDSC2	4.9599	6.8981	2.6442	1.2845
RVH-421	GDSC2	4.987	6.4359	2.839	0.5095
COLO 829	GDSC2	5.1229	7.0843	2.6457	1.1184
WM115	GDSC2	5.1366	6.6196	2.8315	0.4454
WM35	GDSC2	5.1513	8.6461	1.9857	4.3804
HMV-II	GDSC2	5.1648	7.3863	2.5426	1.5196
DJM-1	GDSC2	5.1813	7.4364	2.5299	1.5587
M14	GDSC2	5.1837	9.6862	1.5253	6.9008
SK-MEL-24	GDSC2	5.2155	7.3341	2.5882	1.2704
MMAc-SF	GDSC2	5.2423	6.9103	2.7661	0.5841
CP66-MEL	GDSC2	5.2888	6.6928	2.8644	0.2887
A-431	GDSC2	5.3412	7.8635	2.4314	1.8302
MZ-MEL-2	GDSC2	5.3732	7.638	2.5393	1.3253
G-mel	GDSC2	5.3807	7.1491	2.7335	0.6026
IST-MEL1	GDSC2	5.3908	8.228	2.303	2.377
LB373-MEL-D	GDSC2	5.395	6.9462	2.8141	0.3663
SH-4	GDSC2	5.4247	7.5281	2.6066	1.0128
UACC-257	GDSC2	5.4414	6.9884	2.8168	0.3398
COLO 783	GDSC2	5.4603	7.0298	2.8092	0.3504
WM1552C	GDSC2	5.5171	6.9626	2.8543	0.2307
A101D	GDSC2	5.5317	6.7189	2.9429	0.09
CHL-1	GDSC2	5.5427	7.4983	2.669	0.7078
IGR-1	GDSC2	5.5917	7.1054	2.8317	0.2517
COLO 800	GDSC2	5.5979	9.2828	1.9564	3.8434
LB2518-MEL	GDSC2	5.5997	6.8916	2.9083	0.1214
CP50-MEL-B	GDSC2	5.6567	7.1509	2.8397	0.2168
WM278	GDSC2	5.6868	7.5651	2.7029	0.5233
MeWo	GDSC2	5.744	7.4019	2.7838	0.2996
MZ-MEL-7	GDSC2	5.8039	7.5967	2.7371	0.3819
Hs 938.T	GDSC2	5.8057	7.4132	2.8026	0.2422
COLO 679	GDSC2	5.8796	7.4119	2.8297	0.1765
A-388	GDSC2	5.9601	8.0524	2.6325	0.5805
451Lu	GDSC2	5.9637	7.5637	2.8076	0.1916
COLO 792	GDSC2	6.1611	8.1705	2.6678	0.4025
LOX-IMVI	GDSC2; CTRP2	8.0922	9.7092	6.4309	1.0337
SK-MEL-28	GDSC2; CTRP2	8.3188	9.1137	6.7666	0.0663
IPC-298	GDSC2; CTRP2	8.4083	9.4768	6.6714	0.1829
Mel JuSo	GDSC2; CTRP2	8.5611	10.5396	6.3201	1.0023
Hs 852.T	CTRP2	8.5709	10.5191	6.3336	0.9532
SK-MEL-30	GDSC2; CTRP2	8.5927	10.3036	6.4325	0.6507
Hs 936.T	CTRP2	8.6664	10.0907	6.5479	0.3304
WM1799	CTRP2	8.7085	9.9987	6.5989	0.2163
MDA-MB-435S	CTRP2	8.7289	10.2298	6.5214	0.361
SK-MEL-31	GDSC2; CTRP2	8.8166	19.9399	1.9911	16.7803
Mel Ho	GDSC2; CTRP2	8.8589	10.3118	6.5438	0.2668
WM793	GDSC2; CTRP2	8.9266	10.5087	6.4982	0.3304
SK-MEL-1	GDSC2; CTRP2	8.968	10.2035	6.6238	0.1164
SK-MEL-5	GDSC2; CTRP2	9.0486	10.6646	6.4896	0.3033
A-375	GDSC2; CTRP2	9.0501	10.5285	6.5396	0.2158
RPMI-7951	GDSC2; CTRP2	9.2659	10.6696	6.5701	0.1257
Hs 944.T	CTRP2	9.3343	10.873	6.5242	0.1694
G-361	GDSC2; CTRP2	9.4343	11.042	6.5018	0.1779
COLO 741	CTRP2	9.6925	19.2704	2.9556	12.1178
EquiPSC Line K2	GDSC2	6.5704	8.8443	2.5824	0.4405

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC2	4.1483	8.4198	1.4246	9.7378

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Hs 633.T	GDSC2	4.4009	6.226	2.64	2.0107
VA-ES-BJ	GDSC2	4.8455	6.9942	2.5462	1.875
SW982	GDSC2	4.9286	7.9483	2.1709	3.7278
TE 441.T	GDSC2	5.0665	6.3907	2.8877	0.3256
SW684	GDSC2	5.2721	6.581	2.8978	0.2222
GCT	GDSC2	5.3654	14.6976	-0.7658	18.0612
EW-8	GDSC2	5.3695	6.9464	2.8041	0.4038
MFH-ino	GDSC2	5.4456	7.4428	2.649	0.8418
Rh30	GDSC2	5.4652	7.3756	2.6831	0.7117
MES-SA	GDSC2	5.4797	6.7784	2.9046	0.1521
KYM-1	GDSC2	5.4872	6.9529	2.8467	0.2556
HT-1080	GDSC2	5.5136	6.8257	2.9005	0.1507
SK-UT-1	GDSC2	5.7242	7.7319	2.6562	0.6388
SW872	GDSC2	5.7818	7.4582	2.7781	0.2988
G-401	GDSC2	5.8036	9.8759	1.809	4.307
RD	GDSC2	5.9699	13.1825	0.3853	11.4576
G-402	GDSC2	5.9964	10.3928	1.6881	4.6478
SK-LMS-1	GDSC2	6.12	7.9079	2.745	0.258
A-204	GDSC2	6.2348	8.3287	2.6392	0.4396
STS-0421	GDSC2	6.5581	8.9547	2.5381	0.5493
Rh18	CTRP2	8.8381	10.7207	6.3785	0.6501
RKN	GDSC2; CTRP2	8.9085	9.9545	6.6879	0.06
Rh41	GDSC2; CTRP2	9.0401	10.3015	6.616	0.1126

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TMK-1	GDSC2	4.2155	7.8037	1.7751	7.4601
HGC-27	GDSC2	5.0014	7.16	2.5559	1.6395
MKN28	GDSC2	5.0167	8.2685	2.0776	4.0972
Hs 746.T	GDSC2	5.089	9.1551	1.7136	6.0134
MKN1	GDSC2	5.3179	6.9728	2.7737	0.5159
SNU-1	GDSC2	5.3236	7.2373	2.6755	0.8366
SNU-16	GDSC2	5.3653	6.6262	2.916	0.1614
SCH	GDSC2	5.3801	6.6421	2.9159	0.1579
KATO III	GDSC2	5.3816	8.0053	2.3923	1.9646
IM95	GDSC2	5.4858	7.6491	2.5863	1.0402
GCIY	GDSC2	5.5266	7.407	2.6968	0.6296
TGBC11TKB	GDSC2	5.5394	7.6841	2.5963	0.9614
RERF-GC-1B	GDSC2	5.5856	8.6928	2.2058	2.6056
RF-48	GDSC2	5.6146	7.3348	2.7586	0.4093
MKN7	GDSC2	5.6929	7.5679	2.7043	0.5163
HSC-39	GDSC2	5.769	7.2814	2.835	0.1946
SK-GT-2	GDSC2	5.9677	7.8695	2.7019	0.3992
MKN45	GDSC2; CTRP2	7.8781	9.2127	6.5313	0.8883
GSU	CTRP2	7.8985	8.7718	6.7255	0.2781
OCUM-1	GDSC2; CTRP2	8.1979	10.5498	6.1154	2.0602
SNU-620	CTRP2	8.3851	9.6474	6.598	0.3427
NCI-N87	GDSC2; CTRP2	8.5553	13.5741	4.9192	6.2958
NUGC-3	GDSC2; CTRP2	8.6846	10.2971	6.4765	0.4849
SNU-5	GDSC2; CTRP2	8.728	9.9773	6.6143	0.1848
NUGC-4	GDSC2; CTRP2	8.9169	10.8142	6.377	0.6103
ECC12	GDSC2; CTRP2	8.9295	9.9697	6.69	0.0559
ECC10	GDSC2; CTRP2	8.9507	10.4691	6.5225	0.2754
GSS	CTRP2	8.9883	10.3088	6.5945	0.1497
23132/87	GDSC2; CTRP2	9.0882	10.5277	6.5544	0.1833
Fu97	GDSC2; CTRP2	9.1429	10.7904	6.4808	0.2881
AGS	GDSC2; CTRP2	9.282	10.5862	6.6044	0.0872
SNU-668	CTRP2	9.3097	10.4055	6.6741	0.0338
MKN74	CTRP2	9.7186	16.5802	4.2603	7.2758
SNU-719	CTRP2	9.8967	11.404	6.5417	0.069
KE-39	CTRP2	10.5558	12.4891	6.4046	0.1051
SNG-M	GDSC2; CTRP2	9.1016	12.8492	5.6051	2.9527
SNU-1077	CTRP2	9.1838	10.5845	6.5698	0.1413

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
K5	GDSC2	4.5444	6.8094	2.4609	2.7574
IHH-4	GDSC2	4.558	6.6605	2.5355	2.331
ASH-3	GDSC2	5.1876	6.5767	2.8674	0.3233
WRO	GDSC2	5.2899	6.651	2.8798	0.254
HTC-C3	GDSC2	5.4225	7.3974	2.6565	0.8318
FTC-133	GDSC2	5.4305	6.7572	2.8943	0.1817
KMH-2	GDSC2	5.8793	7.5537	2.7805	0.2622
TT2609-C02	GDSC2	6.2009	7.8703	2.7867	0.1705
ML-1 [Human leukemia]	GDSC2; CTRP2	6.4869	12.3227	3.266	11.5729
CAL-62	GDSC2; CTRP2	8.5662	9.7618	6.6295	0.2072
CGTH-W-1	GDSC2; CTRP2	8.9301	10.1676	6.6225	0.1252
BHT-101	GDSC2; CTRP2	9.0017	10.1243	6.6629	0.0703
B-CPAP	GDSC2; CTRP2	9.03	10.175	6.6556	0.0732
TT	GDSC2; CTRP2	9.2011	10.703	6.5346	0.1849
8305C	GDSC2; CTRP2	9.3627	10.9012	6.5248	0.1627
8505C	GDSC2; CTRP2	9.6531	12.9575	5.8546	1.6124

Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SAS	GDSC2	4.5685	6.9058	2.4314	2.8803
SAT [Human HNSCC]	GDSC2	4.6082	7.9361	1.9785	5.4032
BICR 78	GDSC2	4.7384	7.389	2.3124	3.2592
LB771-HNC	GDSC2	4.8525	7.7865	2.1994	3.6958
KON	GDSC2	4.9125	6.8963	2.6217	1.4362
JHU-011	GDSC2	5.1869	9.625	1.556	6.7216
FaDu	GDSC2	5.2634	7.3561	2.6017	1.1699
CAL-27	GDSC2	5.2704	6.4244	2.9515	0.1275
PE/CA-PJ15	GDSC2	5.3122	7.4842	2.5729	1.2432
BICR 22	GDSC2	5.3139	6.7961	2.837	0.3444
JHU-022	GDSC2	5.3205	8.8362	1.9985	4.0394
PCI-15A	GDSC2	5.3422	7.2865	2.6646	0.8622
SKN-3	GDSC2	5.391	7.9268	2.4297	1.7831
NCI-H3118	GDSC2	5.3932	7.6552	2.5417	1.2966
PCI-30	GDSC2	5.402	10.5132	1.2768	7.8715
HSC-2	GDSC2	5.4534	7.1232	2.7725	0.4481
BB49-HNC	GDSC2	5.4677	8.4365	2.2539	2.519
DOK	GDSC2	5.4767	8.0911	2.4037	1.8078
BB30-HNC	GDSC2	5.5108	7.3434	2.7141	0.5857
BICR 31	GDSC2	5.5136	7.3105	2.7275	0.5443
PCI-06A	GDSC2	5.5507	7.6492	2.6147	0.8868
KOSC-2	GDSC2	5.5707	8.431	2.3088	2.136
OSC-19	GDSC2	5.5769	7.1864	2.7975	0.3309
SNU-1066	CTRP2	5.6517	75.9286	-28.5795	45.2635
BICR 10	GDSC2	5.6948	8.129	2.4908	1.2344
SCC-9	GDSC2	5.7451	7.6116	2.709	0.4781
HO-1-N-1	GDSC2	5.7571	7.4869	2.7586	0.3505
HO-1-u-1	GDSC2	5.7584	7.4443	2.7742	0.3151
SCC-15	GDSC2	5.9394	7.8513	2.6976	0.4209
OSC-20	GDSC2	6.0081	8.1062	2.6318	0.5584
UPCI-SCC-090	GDSC2	6.023	7.8751	2.7207	0.3365
PCI-04B	GDSC2	6.0325	8.3199	2.5625	0.7457
SCC-4	GDSC2	6.0355	8.1375	2.6312	0.547
Ca9-22	GDSC2	6.15	8.6396	2.4908	0.9002
JHU-029	GDSC2	6.2128	8.2875	2.6456	0.4336
CAL-33	GDSC2	6.3087	8.0003	2.7804	0.158
HSC-4	GDSC2; CTRP2	8.1403	9.9059	6.3712	1.194
Detroit 562	GDSC2; CTRP2	8.7975	10.5457	6.4292	0.5429
YD-8	CTRP2	8.9089	12.2961	5.7423	2.658
YD-10B	CTRP2	8.9153	10.1555	6.6214	0.1297
HSC-3	GDSC2; CTRP2	9.0141	10.098	6.6761	0.0577
SCC-25	GDSC2; CTRP2	9.0378	12.5451	5.7047	2.6594
SNU-1076	CTRP2	9.1833	10.4441	6.618	0.0878
SNU-899	CTRP2	9.2816	10.6214	6.5922	0.0991
SNU-1214	CTRP2	9.2902	11.0218	6.4542	0.2886
SNU-46	CTRP2	9.3913	11.2463	6.412	0.3314
BHY	GDSC2; CTRP2	9.7379	11.2581	6.536	0.0905
SNU-1041	CTRP2	10.0259	11.3581	6.6	0.0285

Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
J82	GDSC2	4.4471	6.8623	2.3784	3.3855
647V	GDSC2	5.3451	6.597	2.9189	0.1618
HT-1197	GDSC2	5.4076	7.2373	2.7114	0.6563
T24	GDSC2	5.7415	7.7925	2.6406	0.6762
SW780	GDSC2	5.7837	7.5782	2.736	0.3928
253J	CTRP2	7.7051	9.514	6.2892	1.9938
KU-19-19	GDSC2; CTRP2	8.342	9.7035	6.557	0.4656
639V	GDSC2; CTRP2	8.5068	9.6287	6.6547	0.1816
BFTC-905	GDSC2; CTRP2	8.6797	9.7918	6.6621	0.1257
253J-BV	CTRP2	8.8914	10.1043	6.6305	0.1229
RT-112	GDSC2; CTRP2	8.9094	10.6183	6.4497	0.4404
CAL-29	GDSC2; CTRP2	9.0541	10.4157	6.5812	0.1533
JMSU-1	CTRP2	9.1456	10.3652	6.6316	0.0801
RT-4	GDSC2; CTRP2	9.1642	10.8627	6.4627	0.314
5637	GDSC2; CTRP2	9.2037	10.962	6.4419	0.3395
TCCSUP	GDSC2; CTRP2	9.2046	10.8503	6.4832	0.2648
SW1710	GDSC2; CTRP2	9.2064	10.942	6.4503	0.3227
UM-UC-3	GDSC2; CTRP2	9.3709	10.9889	6.4969	0.1989
VM-CUB-1	CTRP2	9.3868	11.5177	6.3087	0.5431
HT-1376	GDSC2; CTRP2	9.5603	11.3955	6.4237	0.2614

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Ca Ski	GDSC2	4.5694	9.8665	1.022	11.0807
C-33 A	GDSC2	4.6101	7.1882	2.3277	3.3886
OMC-1 [Human cervical carcinoma]	GDSC2	4.8075	7.6307	2.2436	3.5261
SiHa	GDSC2	4.8797	6.3711	2.8181	0.6539
TC-YIK	GDSC2	4.8805	16.0537	-1.7963	23.1122
HT-3	GDSC2	4.8823	7.4299	2.3764	2.6914
SKN	GDSC2	5.0075	9.2471	1.6187	6.7092
HEC-1	GDSC2	5.1259	6.6011	2.8341	0.4438
PEO1	GDSC2	5.1457	7.2229	2.6003	1.2868
ACC-OV7	GDSC2	5.2394	9.7879	1.513	6.8642
C-4-I	GDSC2	5.2413	7.5607	2.5079	1.5931
OVCA433	GDSC2	5.2719	7.3714	2.5995	1.1714
OVMIU	GDSC2	5.2816	8.0249	2.3329	2.368
JEG-3	GDSC2	5.2822	7.3932	2.5955	1.1782
DoTc2 4510	GDSC2	5.2847	7.1123	2.707	0.7533
NT2-D1	GDSC2	5.3246	7.2293	2.679	0.8232
BPH-1	GDSC2	5.3807	10.4203	1.3067	7.7469
NEC8	GDSC2	5.3944	7.0833	2.7636	0.5036
NCC-IT	GDSC2	5.4351	6.9463	2.8295	0.3124
SKG-IIIa	GDSC2	5.4408	7.3535	2.6812	0.7343
SW962	GDSC2	5.4427	7.3121	2.6977	0.6783
OVCA420	GDSC2	5.444	9.3713	1.8292	4.755
MS751	GDSC2	5.4897	12.4722	0.403	12.3547
PA-1	GDSC2	5.5007	7.0822	2.8058	0.3418
PWR-1E	GDSC2	5.5311	7.522	2.6551	0.7613
SW954	GDSC2	5.6418	7.2387	2.8034	0.2936
KGN	GDSC2	5.6791	7.8569	2.59	0.8819
DSH1	GDSC2	5.6929	7.724	2.6463	0.6876
JAR	GDSC2	5.7053	7.5231	2.7256	0.4531
SW756	GDSC2	5.7787	7.3112	2.8283	0.2037
OV17R	GDSC2	5.8701	7.8856	2.658	0.5552
JHOS-3	GDSC2	5.9515	7.8247	2.7117	0.3828
HEY	GDSC2	5.955	7.9017	2.6854	0.444
CAL-39	GDSC2	5.9783	7.9466	2.6782	0.4518
ME-180	GDSC2	6.0159	11.0352	1.4119	6.0562
LB831-BLC	GDSC2	6.2002	8.3396	2.622	0.4955
SiSo	GDSC2	6.2291	9.3507	2.2482	1.7309
UWB1.289	GDSC2	6.7383	9.029	2.5798	0.3875
HeLa	GDSC2; CTRP2	8.5705	9.5557	6.7045	0.0935

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cyclophosphamide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
LEE011	DMMX75K	Moderate	Decreased metabolism of Cyclophosphamide caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[23]

Coadministration of a Drug Treating the Disease Different from Cyclophosphamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Cyclophosphamide caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[24]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Repaglinide.	Acute diabete complication [5A2Y]	[25]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Glibenclamide.	Acute diabete complication [5A2Y]	[25]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Tolazamide.	Acute diabete complication [5A2Y]	[25]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Nateglinide.	Acute diabete complication [5A2Y]	[25]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Glipizide.	Acute diabete complication [5A2Y]	[25]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Cyclophosphamide caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Inotersen.	Amyloidosis [5D00]	[26]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Roflumilast.	Asthma [CA23]	[26]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[27]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Cyclophosphamide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
ABT-492	DMJFD2I	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[27]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Cyclophosphamide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Atracurium.	Corneal disease [9A76-9A78]	[30]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Mivacurium.	Corneal disease [9A76-9A78]	[30]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Pancuronium.	Corneal disease [9A76-9A78]	[30]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Cyclophosphamide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[31]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Cyclophosphamide caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Cyclophosphamide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[33]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Cyclophosphamide caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Cyclophosphamide caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Cyclophosphamide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[36]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Cyclophosphamide caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Cyclophosphamide caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Cyclophosphamide caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[38]
Amphotericin B	DMTAJQE	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Amphotericin B.	Fungal infection [1F29-1F2F]	[24]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Cyclophosphamide caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Cyclophosphamide caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Cyclophosphamide caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Cyclophosphamide caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[24]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[41]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[24]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Cyclophosphamide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[42]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Denosumab.	Low bone mass disorder [FB83]	[43]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Cyclophosphamide caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Cyclophosphamide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[44]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Cyclophosphamide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[45]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Clofarabine.	Mature B-cell lymphoma [2A85]	[46]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Cyclophosphamide and Thalidomide.	Multiple myeloma [2A83]	[47]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Tecfidera.	Multiple sclerosis [8A40]	[48]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Siponimod.	Multiple sclerosis [8A40]	[24]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Fingolimod.	Multiple sclerosis [8A40]	[49]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Ocrelizumab.	Multiple sclerosis [8A40]	[50]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Ozanimod.	Multiple sclerosis [8A40]	[26]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Cyclophosphamide caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[51]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[52]
Prasugrel	DM7MT6E	Minor	Decreased metabolism of Cyclophosphamide caused by Prasugrel mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[26]
Modafinil	DMYILBE	Minor	Increased metabolism of Cyclophosphamide caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[53]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Cyclophosphamide caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[54]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Cyclophosphamide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[55]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Cyclophosphamide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[56]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Cyclophosphamide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[57]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Cyclophosphamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[58]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Cyclophosphamide caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[59]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Cyclophosphamide and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[60]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[27]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Canakinumab.	Rheumatoid arthritis [FA20]	[61]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Cyclophosphamide and Rilonacept.	Rheumatoid arthritis [FA20]	[61]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Golimumab.	Rheumatoid arthritis [FA20]	[62]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Cyclophosphamide and Leflunomide.	Rheumatoid arthritis [FA20]	[41]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Cyclophosphamide when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[63]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Cyclophosphamide caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[26]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Cyclophosphamide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[64]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Vecuronium.	Tonus and reflex abnormality [MB47]	[30]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Cisatracurium.	Tonus and reflex abnormality [MB47]	[30]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Rocuronium.	Tonus and reflex abnormality [MB47]	[30]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Cyclophosphamide and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[60]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Cyclophosphamide and Azathioprine.	Transplant rejection [NE84]	[65]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Cyclophosphamide and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[60]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Cyclophosphamide and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[25]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[27]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Plazomicin.	Urinary tract infection [GC08]	[24]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Cyclophosphamide and Ganciclovir.	Virus infection [1A24-1D9Z]	[24]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Cyclophosphamide and Valganciclovir.	Virus infection [1A24-1D9Z]	[24]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Sodium stearyl fumarate	E00545	23665634	lubricant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cyclophosphamide 25 mg capsule	25 mg	Oral Capsule	Oral
Cyclophosphamide 50 mg capsule	50 mg	Oral Capsule	Oral
Cyclophosphamide 25 mg tablet	25 mg	Oral Tablet	Oral
Cyclophosphamide 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Cyclophosphamide FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [8] O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
• [9] Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
• [10] Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
• [11] CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
• [12] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [13] Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
• [14] The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
• [15] Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
• [16] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [17] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [18] Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
• [19] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [20] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [21] Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008 Nov;18(11):1009-15. doi: 10.1097/FPC.0b013e328313aaa4.
• [22] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [23] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
• [24] Cerner Multum, Inc. "Australian Product Information.".
• [25] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [26] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [27] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [28] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [29] Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
• [30] Multum Information Services, Inc. Expert Review Panel.
• [31] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [32] Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
• [33] Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
• [34] Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
• [35] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [36] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [37] Garattini S, Spreafico F "Some examples of interactions between drugs in cancer chemotherapy." Antibiot Chemother 23 (1978): 283-94. [PMID: 348085]
• [38] Chang TK, Yu L, Maurel P, Waxman DJ "Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines." Cancer Res 57 (1997): 1946-54. [PMID: 9157990]
• [39] Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
• [40] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [41] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [42] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [43] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [44] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [45] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [46] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [47] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [48] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [49] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [50] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [51] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [52] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [53] Product Information. Provigil (modafinil). Cephalon, Inc, West Chester, PA.
• [54] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [55] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [56] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [57] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [58] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [59] Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
• [60] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [61] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [62] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [63] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [64] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [65] Shaunak S, Munro JM, Weinbren K, Walport MJ, Cox TM "Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine." Q J Med 67 (1988): 309-17. [PMID: 3060893]